Corbus Pharmaceuticals Holdings

Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its products include candidate, Lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded in April 2009 and is headquartered in Norwood, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.

MicroVision

If January and February are a sign of things to come in 2021, traders and investors are going to make a lot of money this year. 4 hot small cap stocks on the move are Corbus Pharmaceuticals (NASDAQ: CRBP), Medical Marijuana (OTCMKTS: MJNA), Microvision (NASDAQ: MVIS), and Global Battery Metals (OTCMKTS: REZZF).

4 Hot Small Cap Stocks: Corbus Pharmaceuticals (NASDAQ: CRBP) Medical Marijuana (OTC US: MJNA) Microvision (NASDAQ: MVIS) and Global Battery Metals (OTC US: REZZF)

Aphria

Canopy Growth

HEXO Corp

Global X Cannabis ETF

Tilray Brands

Inside the top performing stocks in the top ETF of January.

Cannabis ETF Tops in January: 5 Stocks That Led the Way

Major disappointment last year due to lenabasum not meeting its endpoints in a phase 3 and phase 2 trial. Massive expectation meant that the company had to downsize significantly to keep operations going.

Corbus Pharmaceuticals: Down But Not Out

Norwood, MA, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced it will participate in the New York Academy of Sciences' webinar on January 27, 2021 on the endocannabinoid system as a target for therapeutic agents.

Corbus Pharmaceuticals Announces Presentations at the New York Academy of Sciences Webinar on Targeting the Endocannabinoid System to Treat Human Diseases

Corbus Pharmaceuticals (CRBP) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Corbus Pharmaceuticals (CRBP) Catches Eye: Stock Jumps 7.3%

Investors need to pay close attention to Corbus Pharmaceuticals (CRBP) stock based on the movements in the options market lately.

Implied Volatility Surging for Corbus Pharmaceuticals (CRBP) Stock Options

Investors need to pay close attention to Corbus (CRBP) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Corbus (CRBP) Stock?

Corbus Pharma (CRBP) is seeing massive gains for CRBP stock on Tuesday despite a lack of recent news from the pharmaceuticals company. The post Corbus Pharma: 8 Things for CRBP Stock Investors to Know About the Company appeared first on InvestorPlace.

Corbus Pharma: 8 Things for CRBP Stock Investors to Know About the Company

Norwood, MA, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat at the Jefferies Virtual London Healthcare Conference on Thursday, November 19, 2020 at 12:35 PM EST.

Corbus Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference

Corbus Pharmaceuticals Holdings, Inc. (CRBP) CEO Yuval Cohen on Q3 2020 Results - Earnings Call Transcript

Corbus Pharmaceuticals Holdings, Inc.'s (CRBP) CEO Yuval Cohen On Q3 2020 Results - Quick Version Earnings Call Transcript

Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of -4.88% and -64.01%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Corbus Pharmaceuticals (CRBP) Reports Q3 Loss, Lags Revenue Estimates

Shares of Corbus Pharmaceuticals (NASDAQ:CRBP) decreased 1.6% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share fell 34.37% year over year to ($0.43), which missed the estimate of ($0.42).

Corbus Pharmaceuticals: Q3 Earnings Insights

Norwood, MA, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system (“ECS”), today reported financial results for the third quarter of 2020. The Company also provided clinical, pipeline and corporate updates.

Corbus Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Updates

On Tuesday, November 10, Corbus Pharmaceuticals (NASDAQ: CRBP) will release its latest earnings report. Benzinga's outlook for Corbus Pharmaceuticals is included in the following report.

Corbus Pharmaceuticals's Earnings: A Preview

Norwood, MA, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today presented additional data from the RESOLVE-1 Phase 3 study of lenabasum for the treatment of systemic sclerosis.

Corbus Pharmaceuticals Presents Additional Data from RESOLVE-1 Study in Systemic Sclerosis

Norwood, MA, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that it will report its third quarter financial results on Tuesday, November 10. Corbus management will host a conference call and live audio webcast to discuss the operational and financial results at 8:30 a.m. ET that same day.

Corbus Pharmaceuticals to Report Third Quarter Results on November 10, 2020

Corbus Pharmaceuticals (CRBP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Corbus Pharmaceuticals (CRBP) Expected to Beat Earnings Estimates: Should You Buy?

Norwood, MA, Oct. 23, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced the presentation of the preliminary data from its 28 week Phase 2b study of lenabasum in patients with cystic fibrosis (CF) at the North American Cystic Fibrosis Conference (NACFC) held online, Oct 7-23, 2020. The data are being presented in poster number 817 titled: “CB2 Agonist, Lenabasum, for the Treatment of Pulmonary Exacerbations in Cystic Fibrosis.” These data can be found at the following link: NACFC Poster #817

Corbus Pharmaceuticals Announces Presentation of Data from its Phase 2b Study in Cystic Fibrosis at NACFC 2020

Norwood, MA, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced the presentation of three abstracts at the American College of Rheumatology (“ACR”) Convergence 2020 being held online, November 5–9, 2020.

Corbus Pharmaceuticals Announces Three Lenabasum Abstracts to be Presented at ACR Convergence 2020

Norwood, MA, Oct. 08, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system (“ECS”), today announced a restructuring of its workforce designed to reallocate capital to certain clinical and preclinical programs.

Corbus Pharmaceuticals Announces Corporate Restructuring and Pipeline Portfolio Updates

Corbus (CRBP) releases disappointing top-line results from its 28-week phase IIb study of lenabasum in patients with cystic fibrosis.

Corbus Stock Down as Lenabasum Fails to Meet Primary Endpoint

Norwood, MA, Oct. 06, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced topline results from its 28-week Phase 2b study of lenabasum in patients with cystic fibrosis (CF). The study enrolled patients in the U.S., Canada and Europe at high risk for recurrent pulmonary exacerbations (PEx). Subjects received lenabasum or placebo added to their background treatments for CF.

Corbus Pharmaceuticals Announces Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis Did Not Meet Primary Endpoint

Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) shares were plummeting hard Tuesday following an adverse clinical data readout.

Why Corbus Pharma Shares Are Sinking

A late-stage clinical failure is weighing heavily on the biotech's stock today.

News for Corbus Pharmaceuticals Holdings Stock (CRBP)